Recocam

Country: European Union

Language: English

Source: EMA (European Medicines Agency)

Buy It Now

Active ingredient:

meloxicam

Available from:

Bimeda Animal Health Limited

ATC code:

QM01AC06

INN (International Name):

meloxicam

Therapeutic group:

Horses; Pigs; Cattle

Therapeutic area:

Oxicams

Therapeutic indications:

CattleFor use in acute respiratory infection with appropriate antibiotic therapy to reduce clinical signs in cattle.For use in diarrhoea in combination with oral rehydration therapy to reduce clinical signs in calves of over one week of age and young, non-lactating cattle.For adjunctive therapy in the treatment of acute mastitis, in combination with antibiotic therapy.PigsFor use in noninfectious locomotor disorders to reduce the symptoms of lameness and inflammation.For adjunctive therapy in the treatment of puerperal septicaemia and toxaemia (mastitis-metritis-agalactia syndrome) with appropriate antibiotic therapy.HorsesFor use in the alleviation of inflammation and relief of pain in both acute and chronic musculoskeletal disorders.For the relief of pain associated with equine colic.

Product summary:

Revision: 5

Authorization status:

Authorised

Authorization date:

2011-09-13

Patient Information leaflet

                                17
B. PACKAGE LEAFLET
18
PACKAGE LEAFLET
RECOCAM 20 MG/ML SOLUTION FOR INJECTION FOR CATTLE, PIGS AND HORSES
1.
NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER AND OF
THE MANUFACTURING AUTHORISATION HOLDER RESPONSIBLE FOR BATCH
RELEASE, IF DIFFERENT
Marketing authorisation holder and manufacturer responsible for batch
release:
Bimeda Animal Health Limited,
2, 3 & 4 Airton Close,
Tallaght, Dublin 24,
Ireland.
2.
NAME OF THE VETERINARY MEDICINAL PRODUCT
Recocam 20 mg/ml solution for injection for cattle, pigs and horses
Meloxicam
3.
STATEMENT OF THE ACTIVE SUBSTANCE(S) AND OTHER INGREDIENT(S)
One ml contains:
ACTIVE SUBSTANCE:
Meloxicam
20 mg
EXCIPIENT:
Ethanol 99.9%
150 mg
Clear, yellow solution
4.
INDICATION(S)
Cattle
For use in acute respiratory infection with appropriate antibiotic
therapy to reduce clinical signs in cattle.
For use in diarrhoea in combination with oral re-hydration therapy to
reduce clinical signs in calves of
over one week of age and young, non-lactating cattle.
For adjunctive therapy in the treatment of acute mastitis, in
combination with antibiotic therapy.
Pigs
For use in non-infectious locomotor disorders to reduce the symptoms
of lameness and inflammation.
For adjunctive therapy in the treatment of puerperal septicaemia and
toxaemia (mastitis-metritis-agalactia
syndrome) with appropriate antibiotic therapy.
Horses
For use in the alleviation of inflammation and relief of pain in both
acute and chronic musculo-skeletal
disorders.
For the relief of pain associated with equine colic.
5.
CONTRAINDICATIONS
Do not use in horses less than 6 weeks of age.
Do not use in pregnant or lactating mares.
Do not use in horses producing milk for human consumption.
19
Do not use in animals suffering from impaired hepatic, cardiac or
renal function and haemorrhagic
disorders, or where there is evidence of ulcerogenic gastrointestinal
lesions.
Do not use in case of hypersensitivity to the active substance or to
any of the excipients.
For the treatment of diarrhoea in cattle, do not use in animals of
l
                                
                                Read the complete document
                                
                            

Summary of Product characteristics

                                ANNEX I
SUMMARY OF PRODUCT CHARACTERISTICS
2
1.
NAME OF THE VETERINARY MEDICINAL PRODUCT
Recocam 20 mg/ml solution for injection for cattle, pigs and horses
2.
QUALITATIVE AND QUANTITATIVE COMPOSITION
One ml contains:
ACTIVE SUBSTANCE:
Meloxicam
20 mg
EXCIPIENT:
Ethanol
150 mg
For the full list of excipients, see section 6.1.
3.
PHARMACEUTICAL FORM
Solution for injection.
Clear yellow solution.
4.
CLINICAL PARTICULARS
4.1
TARGET SPECIES
Cattle, pigs and horses.
4.2
INDICATIONS FOR USE, SPECIFYING THE TARGET SPECIES
Cattle
For use in acute respiratory infection with appropriate antibiotic
therapy to reduce clinical signs in cattle.
For use in diarrhoea in combination with oral re-hydration therapy to
reduce clinical signs in calves of
over one week of age and young, non-lactating cattle.
For adjunctive therapy in the treatment of acute mastitis, in
combination with antibiotic therapy.
Pigs
For use in non-infectious locomotor disorders to reduce the symptoms
of lameness and inflammation.
For adjunctive therapy in the treatment of puerperal septicaemia and
toxaemia (mastitis-metritis-agalactia
syndrome) with appropriate antibiotic therapy.
Horses
For use in the alleviation of inflammation and relief of pain in both
acute and chronic musculo-skeletal
disorders.
For the relief of pain associated with equine colic.
4.3
CONTRAINDICATIONS
See also section 4.7.
3
Do not use in horses less than 6 weeks of age.
Do not use in animals suffering from impaired hepatic, cardiac or
renal function and haemorrhagic
disorders, or where there is evidence of ulcerogenic gastrointestinal
lesions.
Do not use in cases of hypersensitivity to the active substance or to
any of the excipient(s).
For the treatment of diarrhoea in cattle, do not use in animals of
less than one week of age.
4.4
SPECIAL WARNINGS FOR EACH TARGET SPECIES
None.
4.5
SPECIAL PRECAUTIONS FOR USE
Special precautions for use in animals
If adverse reactions occur, treatment should be discontinued and the
advice of a veterinarian should be
sought.
Avoid use in very severe
                                
                                Read the complete document
                                
                            

Documents in other languages

Patient Information leaflet Patient Information leaflet Bulgarian 24-06-2019
Summary of Product characteristics Summary of Product characteristics Bulgarian 24-06-2019
Public Assessment Report Public Assessment Report Bulgarian 21-07-2013
Patient Information leaflet Patient Information leaflet Spanish 24-06-2019
Public Assessment Report Public Assessment Report Spanish 21-07-2013
Patient Information leaflet Patient Information leaflet Czech 24-06-2019
Public Assessment Report Public Assessment Report Czech 21-07-2013
Patient Information leaflet Patient Information leaflet Danish 24-06-2019
Public Assessment Report Public Assessment Report Danish 21-07-2013
Patient Information leaflet Patient Information leaflet German 24-06-2019
Public Assessment Report Public Assessment Report German 21-07-2013
Patient Information leaflet Patient Information leaflet Estonian 24-06-2019
Public Assessment Report Public Assessment Report Estonian 21-07-2013
Patient Information leaflet Patient Information leaflet Greek 24-06-2019
Public Assessment Report Public Assessment Report Greek 21-07-2013
Patient Information leaflet Patient Information leaflet French 24-06-2019
Public Assessment Report Public Assessment Report French 21-07-2013
Patient Information leaflet Patient Information leaflet Italian 24-06-2019
Public Assessment Report Public Assessment Report Italian 21-07-2013
Patient Information leaflet Patient Information leaflet Latvian 24-06-2019
Public Assessment Report Public Assessment Report Latvian 21-07-2013
Patient Information leaflet Patient Information leaflet Lithuanian 24-06-2019
Summary of Product characteristics Summary of Product characteristics Lithuanian 24-06-2019
Public Assessment Report Public Assessment Report Lithuanian 21-07-2013
Patient Information leaflet Patient Information leaflet Hungarian 24-06-2019
Summary of Product characteristics Summary of Product characteristics Hungarian 24-06-2019
Public Assessment Report Public Assessment Report Hungarian 21-07-2013
Patient Information leaflet Patient Information leaflet Maltese 24-06-2019
Public Assessment Report Public Assessment Report Maltese 21-07-2013
Patient Information leaflet Patient Information leaflet Dutch 24-06-2019
Public Assessment Report Public Assessment Report Dutch 21-07-2013
Patient Information leaflet Patient Information leaflet Polish 24-06-2019
Public Assessment Report Public Assessment Report Polish 21-07-2013
Patient Information leaflet Patient Information leaflet Portuguese 24-06-2019
Summary of Product characteristics Summary of Product characteristics Portuguese 24-06-2019
Public Assessment Report Public Assessment Report Portuguese 21-07-2013
Patient Information leaflet Patient Information leaflet Romanian 24-06-2019
Public Assessment Report Public Assessment Report Romanian 21-07-2013
Patient Information leaflet Patient Information leaflet Slovak 24-06-2019
Public Assessment Report Public Assessment Report Slovak 21-07-2013
Patient Information leaflet Patient Information leaflet Slovenian 24-06-2019
Summary of Product characteristics Summary of Product characteristics Slovenian 24-06-2019
Public Assessment Report Public Assessment Report Slovenian 21-07-2013
Patient Information leaflet Patient Information leaflet Finnish 24-06-2019
Public Assessment Report Public Assessment Report Finnish 21-07-2013
Patient Information leaflet Patient Information leaflet Swedish 24-06-2019
Public Assessment Report Public Assessment Report Swedish 21-07-2013
Patient Information leaflet Patient Information leaflet Norwegian 24-06-2019
Summary of Product characteristics Summary of Product characteristics Norwegian 24-06-2019
Patient Information leaflet Patient Information leaflet Icelandic 24-06-2019
Summary of Product characteristics Summary of Product characteristics Icelandic 24-06-2019
Patient Information leaflet Patient Information leaflet Croatian 24-06-2019

Search alerts related to this product

View documents history